{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-290725","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.777523+00:00","generated_at":"2026-06-07T16:03:45.296941+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst Pharma appoints Michael Kalb as CFO; Alicia Grande to retire at year-end 2023","bullets":["Alicia Grande to retire as CFO at end of 2023; will remain as consultant through Dec 31, 2024.","Michael W. Kalb appointed EVP & CFO effective Jan 1, 2024; base salary $525k, bonus up to 50%, equity grant $3M.","Dr. Steven Miller promoted to EVP, Chief Operating & Scientific Officer; Jeffrey Del Carmen to EVP, Chief Commercial Officer.","Kalb has 30+ years pharma/finance experience, previously CFO of Impel, CinCor, and Amarin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-290725","json":"https://secwatch.observer/filing/0001193125-23-290725.json","markdown":"https://secwatch.observer/filing/0001193125-23-290725.md","text":"https://secwatch.observer/filing/0001193125-23-290725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/d418309d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:03:45.296941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d8fa512be","claim":"Michael W. Kalb was appointed as Executive Vice President and Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"On December 4, 2023, the Company announced the appointment of Michael W. Kalb as the Company's Executive Vice President and CFO, effective January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"5a91b0377a","claim":"Jeffrey Del Carmen changed role as Executive Vice President, Chief Commercial Officer at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"and of Jeffrey Del Carmen to Executive Vice President, Chief Commercial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Executive Vice President, Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"783bcbb4ba","claim":"Alicia Grande retired as Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"On December 1, 2023, Alicia Grande, the Chief Financial Officer (\"CFO\") of Catalyst Pharmaceuticals, Inc. (the \" Company \") informed the Company of her intent to retire as the Company's CFO at the end of 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"be13d61240","claim":"Steven Miller changed role as Executive Vice President, Chief Operating and Scientific Officer at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"the Company reported the promotion, effective on January 1, 2024, of Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Executive Vice President, Chief Operating and Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}